Drug Prices
-
Caught my eye — 1/24/25
Read more: Caught my eye — 1/24/25I am pretty sure January is actually the whole first half of the year. Bears and hibernation might have the right idea. Old Hat Already: I hit send last week and the Centers for Medicare & Medicaid Services (CMS) released the list of 2027 Medicare negotiated drugs. Overall it felt like just another announcement with…
-
340B, Caught my eye, Drug Prices, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Pharmacy Benefit ManagersCaught my eye — 1/10/25
Read more: Caught my eye — 1/10/25There are some weeks where your long-term success could be impacted if you’re not on top of what’s happening, this isn’t one of those weeks. But these things are cumulative so, if need help on the regular with strategy and health policy (like figuring out what you need to pay attention to, help understanding the…
-
Caught my eye — 12/13/24
Read more: Caught my eye — 12/13/24Methodology Matters. The Institute for Clinical and Economic Review (ICER) released their annual Unsupported Price Increase report and I find the whole process maddening. The inflationary metric they used was medical, not general (CPI-U). You might think that didn’t matter but it does. You know what medical inflation was? 0.48%. So anything over 2.48% increase…
-
Caught my eye — 12/6/24
Read more: Caught my eye — 12/6/24When your job is to stay on top of the news but you also just want to turtle a little bit, there are challenges that eventually have to be faced. Skimming the news, here is what caught my eye… 340B Bonanza. I have been devouring the 340B coverage of J&J, Lilly and BMS suing the…
-
Caught my eye, Drug Prices, Healthcare Costs, Inflation Reduction Act, Medicare Negotiation, Medicare Part DCaught my eye — 11/22/24
Read more: Caught my eye — 11/22/24As we look ahead to next week and Thanksgiving, I have to say thank you to you for subscribing and reading. I got the stuffing knocked out of me this summer but knowing that this group of subscribers hangs in there and continues to read is nice. As I look ahead to the next year,…
-
Caught my eye — 11/1/24
Read more: Caught my eye — 11/1/24As I write this, the elementary school across the street has Thriller playing at the 5th grade Halloween party happening in the parking lot. Things change and they stay the same. Not the worst reminder this week. Waiting. Payment rules expected from the Centers for Medicare & Medicaid Services plus maybe eventually the Medicare Transaction…
-
340B, Caught my eye, Drug Prices, Inflation Reduction Act, Medicare Negotiation, Medicare Part D, Medicare Transaction Facilitator, Medicare Transaction FacilitatorCaught my eye — 10/18/24
Read more: Caught my eye — 10/18/24Order (Not) Ready. The National Community Pharmacists Association surveyed just under 500 independent pharmacy owners and the results are really interesting. Almost ¾ had not signed 2025 Part D pharmacy contracts as of about a month ago. Of those that dispense GLP-1 agonists, 96% lose money on them; it makes sense why 59% are thinking…
-
Biosimilars, Caught my eye, CMMI, Drug Prices, Employers, Healthcare Costs, Obesity, Pharmacy Benefit ManagersCaught my eye — 9/27/24
Read more: Caught my eye — 9/27/24If you haven’t trained your teams on Medicare Part D changes for 2025, hop to it. Or reach out to me. These are January 1 issues and we’re about to hit October…. Let me clear my throat. The STAT news breaking news headline read “Sanders says pharmacy benefit managers (PBMs) won’t penalize Novo for cutting…
-
340B, Caught my eye, Drug Prices, Healthcare Costs, Inflation Reduction Act, Medicare Advantage, Medicare Negotiation, Medicare Part DCaught my eye — 9/20/24
Read more: Caught my eye — 9/20/24Adding On. So glad to see this research from Avalere conducted on behalf of the Community Oncology Alliance (COA) on the impact of the Inflation Reduction Act (IRA) negotiation on Medicare Part B provider reimbursement. While in Medicare Part D, negotiated prices do not factor into Average Manufacturer Price, the legislation is silent on whether…
-
Caught my eye — 9/13/24
Read more: Caught my eye — 9/13/24On the pile. 46Brooklyn put out a piece demonstrating the difficulty of understanding drug prices. It is a doozy of a read. A set-aside-time-to-concentrate read. But if you are skeptical about drug pricing and want to lump it all on manufacturers, you should take the time to read it. Big picture, there is no single…
Latest news
- Caught my eye — 1/24/25
- Caught my eye — 1/16/25
- Caught my eye — 1/10/25
- Caught my eye — 12/20/24
- Nurturing the Potential of Biosimilars
Categories
- 340B (31)
- Affordable Care Act (3)
- Alzheimer's (4)
- Biosimilars (19)
- Caught my eye (53)
- Chevron Deference (2)
- CMMI (8)
- Copay Accumulators (6)
- COVID (2)
- Drug Prices (28)
- Drug shortages (7)
- DTC (2)
- Employers (7)
- Generics (4)
- Health Equity (3)
- Healthcare Costs (24)
- ICER (7)
- Importation (2)
- Inflation Reduction Act (42)
- Insulin (4)
- IP (3)
- Long term care (1)
- Medicaid (3)
- Medicare Advantage (13)
- Medicare Negotiation (44)
- Medicare Part D (40)
- Medicare Transaction Facilitator (2)
- Medicare Transaction Facilitator (6)
- Obesity (18)
- On the Horizon (1)
- Orphan Drugs (2)
- Pharmacy Benefit Managers (25)
- Reference Pricing (4)
- State-based Reform (13)
- Uncategorized (4)
- Utilization Management (1)
- Vaccines (2)
- Value (8)